Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
stock ticker
|
| gptkbp:acquiredBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:acquisitionYear |
2012
|
| gptkbp:focus |
diabetes treatment
|
| gptkbp:foundedYear |
1987
|
| gptkbp:hasCompany |
Amylin Pharmaceuticals, Inc.
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMLN
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Bydureon
gptkb:Byetta gptkb:Symlin |
| gptkbp:refersTo |
gptkb:Amylin_Pharmaceuticals
|
| gptkbp:status |
acquired
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:bfsParent |
gptkb:Amylin_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|